DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20184315

A randomised double blind placebo controlled trial to assess the efficacy and tolerability of short course of ornidazole in diarrhoea predominant irritable bowel syndrome

Preetha Jose, Narayanan P. V., Varghese Thomas

Abstract


Background: Irritable bowel syndrome is a common disorder affecting the general population. At present the treatment is mainly symptomatic as the pathophysiology is not clear. Abnormal flora especially small bowel bacterial over growth is considered as one of the causes. A short course of ornidazole is compared with placebo to assess its efficacy and tolerability in diarrhoea predominant irritable bowel syndrome.

Methods: This was a randomised double-blind placebo controlled trial done in the Departments of Gastroenterology and Pharmacology at Government Medical College, Calicut. Patients were randomly assigned to two groups to receive either ornidazole or Placebo. The baseline symptoms were recorded and graded to get a global symptom score. Patients assigned to ornidazole group received 500mg twice daily orally for 5 days and the control group received identical looking placebo tablets. The patients were reassessed every week for four weeks. The patients subjective global assessment of relief and global symptom score was recorded. Statistical analysis was done using Wilcoxon signed Rank test and Mann Whitney U test.

Results: This study was done in twenty patients with a mean age of 30 with comparable baseline characteristics and symptom scores (p=0.969). Ornidazole produced a highly significant reduction in the global symptom score (p<0.001) compared to placebo. It was maintained through the four weeks follow up. No serious adverse effects were reported. Two patients reported burning sensation in the stomach which was self limited.

Conclusions: Ornidazole is efficacious than placebo in controlling the symptoms of diarrhoea predominant irritable bowel syndrome and is well tolerated.


Keywords


Diarrhoea predominant irritable bowel syndrome, Global symptom score, IBS-D, Ornidazole, Placebo

Full Text:

PDF

References


Longstreth GL, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders, Gastroenterology. 2006;130:1480-91.

Drossman D, Camilleri M, Mayer E, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108.

Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, et al. Systematic review on the management of irritable bowel syndrome in North America. Ame J Gastroenterol. 2002;97(Suppl):S7-S26.

Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130(5):1377-90.

Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Alosetron for the treatment of Irritable bowel syndrome in women and men. Ameta analysis of 8 randomised placebo controlled, 12 week trials Clinical Therapeutics. 2008;30(5):884-901.

Sleisenger and Fodtran’s Gastrointestinal and liver disease. Mark Feldman, Lawrence. S. Friedman and Lawrence, J. Brandt. 8th ed. Saunders, Philadelphia; 2006;2:2645.

Madden JAJ, Hunter JO. A review of the role of the gut flora in irritable bowel syndrome and effects of probiotics. British Journal of Nutrition. 2002;88 (Suppl1):S67-S72.

Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Ame J Gastroenterol. 2000;95(12):3504-6.

Pimentel M, Park S, Mirocha J, Kane S, Kong, Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557-63.

Pimentel M, Chow EJ, Lin HC. Normalisation of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double blind randomized placebo controlled study. American J Gastroenterol. 2003;98(2):412-9.

Tripathi KD. Essentials of Medical Pharmacology. 6th ed. Jaypee Brothers, New Delhi; 2008:798-800.

Dale M. The complete drug reference. 23rd ed. Pharmaceutical Peers. 2002:596-599.

Kim HJ, Camilleri M, McKinzie MB, Lempke MB, Burton DD, Thomforde GM, et al. A randomized controlled trial of a probiotic VSL #s on gut transit and symptoms in diarrhea predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method of estimating the probability of adverse drug reactions. Clinical pharmacology and therapeutics. 1981;30:239-45.